Cencora, the healthcare distributor trading on NYSE under ticker COR, maintains strong fundamentals despite recent price pullback. The company boasts a global brand presence, serves critical clinical needs, and demonstrates solid profitability across thin margins. Analysts reaffirm buy ratings for 2025 based on compelling dividend growth, with a proven ten-year track record across multiple market cycles and conservative payout ratios. Fitch assigned an A-level credit rating, reflecting financial strength. Recent strategic moves include a 1.1 billion dollar acquisition of EyeSouth's retina-care business, expanding market reach. Sector headwinds include regulatory risks and pricing pressures that warrant monitoring.
Post from MarketNews_en
Log in to interact with content.